4D Molecular Therapeutics, Inc. (FDMT): Capital Expenditures
$536.0K
Year ended 2025-12-31
-64.0%
3-year compound annual growth
-11.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $536.0K | -85.8% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $3.79M | +36.6% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $2.77M | -76.0% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $11.54M | +26.6% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $9.11M | +811.0% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $1.00M | -68.8% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $3.20M | n/a | 2021-03-25, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $536.0K | -85.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $19.04M | -13.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $6.47M | -52.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $848.0K | +450.6% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
Compare FDMT, MGTX, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗